Fundraising Fox

Artax Biopharma

Cambridge, US · Founded 2013 · 3 known investors

artaxbiopharma.com ↗

Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression. Its lead candidate AX-158 has shown Phase 2a data in psoriasis, with additional Phase 2 trials planned in atopic dermatitis and rheumatoid arthritis.

BiotechHealthtech

Founders & leadership

JS
Joe SuarezExecutive Officer
MN
Maria NicholExecutive Officer
RW
Robert W. Armstrong, Ph.D.Executive Officer, Director
DT
Damia TormoPresident, CEO, Treasurer and Founder
HT
Henri TermeerDirector
PB
Peter B. FinnSecretary
JG
Javier GarciaDirector
RA
Rob ArmstrongCEO
AH
Andre HoekemaDirector
AW
Alan WaltsDirector
DT
Damia Tormo, Ph.D.Director
CB
Casper BreumDirector

Investors · 3

Sound BioventuresMalmö
Advent Life SciencesreportedLondonvia Raj Parekh · board
Columbus Venture PartnersreportedValenciavia Jose Mesa · inferred

Reported raises · per SEC filings

Form D private placements
▶$19MraisedMay 2026 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joe SuarezExecutive Officer
  • Andre HoekemaDirector
  • Maria NicholExecutive Officer
  • Alan WaltsDirector
  • Damia Tormo, Ph.D.Director
  • Gino SantiniDirector
  • Casper BreumDirector
  • Raj ParekhDirector
  • Robert W. Armstrong, Ph.D.Executive Officer, Director
Offering amount
$19M
Amount sold
$19M
Proceeds to insiders
$3.5M
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.8MraisedMay 2022 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan E. WaltsDirector
  • Raj ParekhDirector
  • Joseph M. LobackiExecutive Officer, Director
  • Casper BreumDirector
  • Robert Armstrong, Ph.D.Director
  • Gino SantiniDirector
  • Damia Tormo, Ph.D.Director
Offering amount
$25.8M
Amount sold
$25.8M
First sale
Dec 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedFeb 2021 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gino SantiniDirector
  • Damia TormoDirector
  • Joseph M. LobackiExecutive Officer, Director
  • Robert Armstrong, Ph.D.Director
  • Alan E. WaltsDirector
Offering amount
$3M
Amount sold
$2.2M
First sale
Feb 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedMay 2020 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan E. WaltsDirector
  • Joseph M. LobackiExecutive Officer, Director
  • Javier GarciaDirector
  • Robert Armstrong, Ph.D.Director
  • Gino SantiniDirector
  • Damia Tormo, Ph.D.Director
Offering amount
$2M
Amount sold
$2M
First sale
Apr 2020
Incorporated
Corporation, Massachusetts
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$750KraisedAug 2019 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Damia Tormo, Ph.D., MBMExecutive Officer, Director
  • Robert Armstrong, Ph.D.Director
  • Alan E. WaltsDirector
  • Gino SantiniDirector
  • Javier GarciaDirector
Offering amount
$3.5M
Amount sold
$750K
First sale
Jul 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedOct 2015 · 29 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Raj ParekhDirector
  • Gino SantiniDirector
  • Damia TormoExecutive Officer, Director
  • Henri TermeerDirector
  • Peter B. FinnExecutive Officer
  • Javier GarciaDirector
  • Robert W. Armstrong, Ph.D.Director
Offering amount
$10M
Amount sold
$3M
Minimum investment
$5K
Proceeds to insiders
$250K
First sale
Jul 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.